Evaluation of Bis-Benzimidazoles in the Treatment of Murine Lymphocytic Choriomeningitis Virus Infections

AUTOR(ES)

Stella, J. P.

RESUMO

Seventy percent of the mice receiving (S,S)-1,2-bis(5-methoxy-2-benzimidazolyl)-1,2-ethandiol (A36683) in their drinking water lived at least four times longer than control mice when infected with 10 or 100 mean lethal doses of lymphocytic choriomeningitis virus strain UBC. In the next 4 months, most of the survivors died with lymphocytic choriomeningitis-like symptoms. Drug treatment during the first 7 days after infection was found to have no significant effect on virus titers in various organs. The sparing effect of the drug is discussed in terms of immunosuppression.

Documentos Relacionados

• Characteristics of the In Vitro Inhibition of Arenavirus Synthesis by Bis-Benzimidazoles
• Simple, mild, and highly efficient synthesis of 2-substituted benzimidazoles and bis-benzimidazoles
• Activity of cationically substituted bis-benzimidazoles against experimental Pneumocystis carinii pneumonia.
• Structure-In Vitro Activity Relationships of Pentamidine Analogues and Dication-Substituted Bis-Benzimidazoles as New Antifungal Agents
• Structure-activity studies of dicationically substituted bis-benzimidazoles against Giardia lamblia: correlation of antigiardial activity with DNA binding affinity and giardial topoisomerase II inhibition.